Abstract 3583
Background
Tumor Associated Macrophages (TAMs) and ARF-MDM2 pathway seem to be interconnected actors in malignant pleural mesothelioma (MPM) pathogenesis, treatment outcome and prognosis. On the basis of such evidence, this prospective study aims at comparing tumor immune microenvironment (TME) and checkpoint expression (PD-L1) in naïve tumor samples and immune cells in blood samples of ARF+ vs. ARF- MPM.
Methods
Tumor samples were collected at the baseline (T0) in all enrolled patients and at the time of surgery (T1) in resectable patients. Immunohistochemistry was carried out to evaluate p14/ARF, PD-L1, CD3+, CD4+, CD8+ T lymphocytes; CD20+ B-lymphocytes; CD68+ macrophages. Blood samples were collected in a subset of patients at T0 and T1 and analyzed for CD3+CD4+, CD3+CD8+, CD4+CD25+FoxP3+ peripheral T lymphocytes, CD68 + (total) and CD163 + (M2-like) peripheral monocytes by flow cytometry analysis.
Results
Preliminary data on the first 52 chemonaive MPM samples (32 epithelioid, 16 biphasic and 4 sarcomatoid) were evaluated. P14/ARF was detected in 11 patients (21%). P14/ARF+ cases were characterized by higher CD4+ T-lymphocyte percentage (median value 10% vs 1%, p = 0.05), mainly in peritumoral areas, while p14/ARF – cases were characterized by higher CD163+ M2 macrophages percentage (50% vs 40% in p14/ARF+ cases) and higher CD163+/CD68+ ratio (1.3 vs. 1 in p14/ARF+ cases), even though without statistical significance. Paired (T0 and T1) blood samples of five patients were also assessed for CD8+ and CD4+CD25+FoxP3+ T-reg lymphocytes levels change before and after chemotherapy. We observed a T-reg decrease in 2 patients achieving a disease control to first-line platinum-based chemotherapy, while an increase in 3 progressing patients, without major difference between p14/ARF + and p14/ARF- cases.
Conclusions
p14ARF+ MPM samples seem to be characterized by lower CD163+ M2-polarized macrophages and higher CD4+ T lymphocytes. The amount of T-reg in blood samples may be useful to anticipate radiological and/or clinical progression to chemotherapy. Larger case series and wider TME characterization in tissue and immune cells quantification in blood samples are needed to validate our preliminary findings and will be presented at the conference.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Istituto Oncologico Veneto IRCCS.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract